Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$86.72 USD

86.72
4,365,080

-0.64 (-0.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sheraz Mian headshot

Previewing the Q1 Earnings Season

Is the earnings picture really as bad as some are suggesting it is?

    Sheraz Mian headshot

    Q2 Earnings Season in Rearview Mirror

    Q2's earnings growth strength has been broad-based and driven by top-line gains.

      Sheraz Mian headshot

      Record Earnings & Stronger Growth in Q2

      The 2014 Q2 earnings season is moving towards the finish line.

        Sheraz Mian headshot

        Strong Earnings Season Winding Down

        It's been tough for the retailers in recent quarters and Q2 is no different.

          Kevin Matras headshot

          What is Your Stock's Earnings Yield?

          Kevin Matras talks about a stock's Earnings Yield and how to use it. Highlighted stocks include GILD, LYB, MGA, RFMD and UAL.

            Sheraz Mian headshot

            Q3 Earnings Estimates Not Falling As Much

            The reduced negative revisions rate at this stage in the reporting cycle is the most notable positive element of this earnings season.

              Sheraz Mian headshot

              Can the Earnings Rebound be Sustained?

              The 2014 Q2 earnings season is presenting a much improved picture.

                Sheraz Mian headshot

                Closing the Books on Q1 Earnings Season

                What we saw this earnings season was anemic growth and continuation of the negative guidance.

                  Sheraz Mian headshot

                  Another Weak Earnings Season Coming to an End

                  What we saw this earnings season was anemic growth and continuation of the negative guidance.

                    Sheraz Mian headshot

                    Q1 Earnings Season Coming to an End

                    What we saw this earnings season was anemic growth and continuation of the negative guidance.

                      Sheraz Mian headshot

                      Q1 Earnings Season in Final Stretch

                      Earnings growth has been hard to come by for some time.

                        Sheraz Mian headshot

                        Q2 Earnings Estimates Coming Down

                        Earnings growth has been hard to come by for some time.

                          Sheraz Mian headshot

                          An Improving, But Still Weak Earnings Picture

                          There is still plenty that is disappointing about the Q1 earnings.